Biology and Management of Acute Graft-Versus-Host Disease

  • Robert Korngold
  • Joseph H. Antin
Part of the Cancer Treatment and Research book series (CTAR, volume 144)


Extensive investigations over the last 25 years of the basic biology of acute graft-versus-host disease (GvHD) in murine models of allogeneic blood and marrow transplantation (BMT), particularly in major histocompatibility complex (MHC)-matched, minor histocompatibility antigen (miHA) different strain combinations, has brought us to an understanding of much of the etiology and pathogenesis of this disease. The relative contributions of mature donor CD4+ and CD8+T cells in causing the development of GvHD across different histocompatibility barriers has been clarified and the involvement of host conditioning factors and the requirements for inflammatory cytokines at early stages after transplant are now appreciated. We also now have a reasonable understanding of what miHA are and how T cells recognize them, although which particular minor H antigens elicit severe GvHD responses in mice is still far from clear. Overall, the elucidation of the complex aspects of GvHD...


Major Histocompatibility Complex Major Histocompatibility Complex Class Conditioning Regimen Acute GvHD Chronic GvHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tan JT, Ha J, Cho HR, et al. Analysis of expression and function of the costimulatory molecule 4-1bb in alloimmune responses. Transplantation 2000;70:175–83.PubMedGoogle Scholar
  2. 2.
    Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007;25:171–92.PubMedGoogle Scholar
  3. 3.
    Golding H, Munitz TI, Singer A. Characterization of antigen-specific, Ia-restricted, l3t4+ cytolytic T lymphocytes and assessment of thymic influence on their self specificity. J Exp Med. 1985;162:943–61.PubMedGoogle Scholar
  4. 4.
    Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150:197–214.PubMedGoogle Scholar
  5. 5.
    Sprent J, Boehmer HV, Nabholz M. Association of immunity and tolerance to host H-2 determinants in irradiated F1 hybrid mice reconstituted with bone marrow cells from one parental strain. J Exp Med. 1975;142:321–31.PubMedGoogle Scholar
  6. 6.
    Bortin MM. A compendium of reported human bone marrow transplants. Transplantation 1970;9:571–87.PubMedGoogle Scholar
  7. 7.
    Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687–98.PubMedGoogle Scholar
  8. 8.
    Hamilton BL, Bevan MJ, Parkman R. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J Immunol. 1981;126:621–5.PubMedGoogle Scholar
  9. 9.
    Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983;302:159–61.PubMedGoogle Scholar
  10. 10.
    Goulmy E, Voogt P, van Els C, de Bueger M, van Rood J. The role of minor histocompatibility antigens in GvHD and rejection: a mini-review. Bone Marrow Transplant. 1991;7 Suppl 1:49–51.PubMedGoogle Scholar
  11. 11.
    Simpson E, Scott D, James E, et al. Minor H antigens: genes and peptides. Eur J Immunogenet. 2001;28:505–13.PubMedGoogle Scholar
  12. 12.
    Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588–90.PubMedGoogle Scholar
  13. 13.
    Bertinetto FE, Dall’Omo AM, Mazzola GA, et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int J Immunogenet. 2006;33:375–84.PubMedGoogle Scholar
  14. 14.
    O’Reilly R. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol. 1992;29 Suppl 1:20–6.PubMedGoogle Scholar
  15. 15.
    Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989;73:1340–50.PubMedGoogle Scholar
  16. 16.
    Korngold R, Sprent J. Variable capacity of l3t4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165:1552–64.PubMedGoogle Scholar
  17. 17.
    Berger M, Wettstein PJ, Korngold R. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 1994;57:1095–102.PubMedGoogle Scholar
  18. 18.
    Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease. J Invest Dermatol. 1994;102:451–61.PubMedGoogle Scholar
  19. 19.
    Jones SC, Friedman TM, Murphy GF, Korngold R. Specific donor vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol Blood Marrow Transplant. 2004;10:91–105.PubMedGoogle Scholar
  20. 20.
    Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–5.PubMedGoogle Scholar
  21. 21.
    Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987–92.PubMedGoogle Scholar
  22. 22.
    Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347–56.PubMedGoogle Scholar
  23. 23.
    Korngold R, Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med. 1982;155:872–83.PubMedGoogle Scholar
  24. 24.
    Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest. 2003;112:1880–6.PubMedGoogle Scholar
  25. 25.
    Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184:387–96.PubMedGoogle Scholar
  26. 26.
    Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S. Naturally anergic and suppressive CD4+CD25+ T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol. 2000;12:1145–55.PubMedGoogle Scholar
  27. 27.
    Taylor P, Noelle R, Blazar B. CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigens via costimulatory blockade. J Exp Med. 2001;193:1311–7.PubMedGoogle Scholar
  28. 28.
    Johnson B, Becker E, LaBelle J, Truitt R. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol. 1999;163:6479–87.PubMedGoogle Scholar
  29. 29.
    Taylor P, Lees C, Blazar B. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493–9.PubMedGoogle Scholar
  30. 30.
    Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GvHD. Blood 2005;105:2220–6.PubMedGoogle Scholar
  31. 31.
    Albert M, Liu Y, Anasetti C, Yu X. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur J Immunol. 2005;35:2598–607.PubMedGoogle Scholar
  32. 32.
    Jones S, Murphy G, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9:243–56.PubMedGoogle Scholar
  33. 33.
    Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2(10):947–50.PubMedGoogle Scholar
  34. 34.
    Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964–8.PubMedGoogle Scholar
  35. 35.
    Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301–5.PubMedGoogle Scholar
  36. 36.
    Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298–300.PubMedGoogle Scholar
  37. 37.
    van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974;52:401–4.PubMedGoogle Scholar
  38. 38.
    Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effects of a protective environment. N Engl J Med. 1983;308:302–7.PubMedGoogle Scholar
  39. 39.
    Beelen DW, Haralambie E, Brandt H, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992;80:2668–76.PubMedGoogle Scholar
  40. 40.
    Beelen D, Elmaagacli A, Muller K, Hirche H, Schaefer U. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999;93:3267–75.PubMedGoogle Scholar
  41. 41.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–63.PubMedGoogle Scholar
  42. 42.
    Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002;20:1295–303.PubMedGoogle Scholar
  43. 43.
    Flowers ME, Traina F, Storer B, et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant. 2005;35:277–82.PubMedGoogle Scholar
  44. 44.
    Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108:3216–22.PubMedGoogle Scholar
  45. 45.
    Storb R, Epstein R, Graham T, Thomas E. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970;9:240–6.PubMedGoogle Scholar
  46. 46.
    Lazarus HM, Coccia PF, Herzig RH, et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984;64:215–20.PubMedGoogle Scholar
  47. 47.
    Santos GW, Sensenbrenner LL, Burke PJ, et al. Marrow transplanation in man following cyclophosphamide. Transplant Proc. 1971;3:400–4.PubMedGoogle Scholar
  48. 48.
    Ramsay NK, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med. 1982;306:392–7.PubMedGoogle Scholar
  49. 49.
    Luznik L, Fuchs E, Chen A, et al. Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT). Biol Blood Marrow Transplant. 2007;13 Suppl:4.Google Scholar
  50. 50.
    O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.PubMedGoogle Scholar
  51. 51.
    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85–118.PubMedGoogle Scholar
  52. 52.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–400.PubMedGoogle Scholar
  53. 53.
    Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620–9.PubMedGoogle Scholar
  54. 54.
    Basara N, Blau WI, Kiehl MG, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant. 2000;14:121–6.PubMedGoogle Scholar
  55. 55.
    Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192–204.PubMedGoogle Scholar
  56. 56.
    Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–91.PubMedGoogle Scholar
  57. 57.
    Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87.Google Scholar
  58. 58.
    Wagner J, Santos G, Noga S, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990;75:1370–7.PubMedGoogle Scholar
  59. 59.
    Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O’Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986;68:770–3.PubMedGoogle Scholar
  60. 60.
    Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.PubMedGoogle Scholar
  61. 61.
    Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664–72.PubMedGoogle Scholar
  62. 62.
    Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991;78:2139–49.PubMedGoogle Scholar
  63. 63.
    Soiffer RJ, Weller E, Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001;19:1152–9.PubMedGoogle Scholar
  64. 64.
    Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999;94:2192–9.PubMedGoogle Scholar
  65. 65.
    Martin PJ, Pei J, Gooley T, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552–60.PubMedGoogle Scholar
  66. 66.
    Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 1998;91:1083–90.PubMedGoogle Scholar
  67. 67.
    Montero A, Savani BN, Kurlander R, et al. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol. 2005;130:733–9.PubMedGoogle Scholar
  68. 68.
    Greenberg PD, Riddell SR. Deficient cellular immunity—finding and fixing the defects. Science 1999;285:546–51.PubMedGoogle Scholar
  69. 69.
    Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:418–23.PubMedGoogle Scholar
  70. 70.
    Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet 2005;366:733–41.PubMedGoogle Scholar
  71. 71.
    Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002;360:130–7.PubMedGoogle Scholar
  72. 72.
    Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol. 2002;118:108–16.PubMedGoogle Scholar
  73. 73.
    Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–5.PubMedGoogle Scholar
  74. 74.
    Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from gruppo italiano trapianti midollo osseo (GITMO). Blood 2001;98:2942–7.PubMedGoogle Scholar
  75. 75.
    Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865–71.PubMedGoogle Scholar
  76. 76.
    Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007;21:1387–94.PubMedGoogle Scholar
  77. 77.
    Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor dc reconstitution. Blood 2002;99:2586–91.PubMedGoogle Scholar
  78. 78.
    Auffermann-Gretzinger S, Eger L, Schetelig J, Bornhauser M, Heidenreich F, Ehninger G. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation 2007;83:1268–72.PubMedGoogle Scholar
  79. 79.
    Delgado J, Thomson K, Russell N, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724–30.PubMedGoogle Scholar
  80. 80.
    Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–93.PubMedGoogle Scholar
  81. 81.
    Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 2007;110:9–17.PubMedGoogle Scholar
  82. 82.
    Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985;66:698–702.PubMedGoogle Scholar
  83. 83.
    Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft versus host disease in patients given HLA-identical marrow grafts for leukemia: long term followup of a controlled trial. Blood 1989;73:1729–34.PubMedGoogle Scholar
  84. 84.
    Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303–14.PubMedGoogle Scholar
  85. 85.
    Nash R, Antin J, Karanes C, et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062–8.PubMedGoogle Scholar
  86. 86.
    Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant. 2000;6:254–61.PubMedGoogle Scholar
  87. 87.
    Sehgal S. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–40.PubMedGoogle Scholar
  88. 88.
    Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007;109:3108–14.PubMedGoogle Scholar
  89. 89.
    Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007;110:490–500.PubMedGoogle Scholar
  90. 90.
    Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006;107:1149–55.PubMedGoogle Scholar
  91. 91.
    Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331–42.PubMedGoogle Scholar
  92. 92.
    Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929–35.PubMedGoogle Scholar
  93. 93.
    Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43:3–10.PubMedGoogle Scholar
  94. 94.
    Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011–6.PubMedGoogle Scholar
  95. 95.
    Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342–8.PubMedGoogle Scholar
  96. 96.
    Sackstein R. A revision of Billingham’s tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12 Suppl 1:2–8.PubMedGoogle Scholar
  97. 97.
    Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 2006;107:1703–11.PubMedGoogle Scholar
  98. 98.
    Dutt S, Ermann J, Tseng D, et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005;106:4009–15.PubMedGoogle Scholar
  99. 99.
    Hashimoto D, Asakura S, Matsuoka K, et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease. Eur J Immunol. 2007;37:271–81.PubMedGoogle Scholar
  100. 100.
    Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 2003;111:659–69.PubMedGoogle Scholar
  101. 101.
    Shapira MY, Resnick IB, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant. 2005;36:1097–101.PubMedGoogle Scholar
  102. 102.
    Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day + 5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006;107:4177–81.PubMedGoogle Scholar
  103. 103.
    MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–94.PubMedGoogle Scholar
  104. 104.
    MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:40–6.PubMedGoogle Scholar
  105. 105.
    Byers VS, Henslee PJ, Kernan NA, et al. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990;75:1426–32.PubMedGoogle Scholar
  106. 106.
    Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996;88:824–30.PubMedGoogle Scholar
  107. 107.
    Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768–76.PubMedGoogle Scholar
  108. 108.
    Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649–54.PubMedGoogle Scholar
  109. 109.
    McCarthy PL Jr, Williams L, Harris-Bacile M, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation 1996;62:626–31.PubMedGoogle Scholar
  110. 110.
    Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007;109:2657–62.PubMedGoogle Scholar
  111. 111.
    Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004;104:1559–64.PubMedGoogle Scholar
  112. 112.
    Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:441–7.PubMedGoogle Scholar
  113. 113.
    Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. 2006;37:95–9.PubMedGoogle Scholar
  114. 114.
    Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol. 2006;135:382–5.PubMedGoogle Scholar
  115. 115.
    Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83–9.PubMedGoogle Scholar
  116. 116.
    Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:1224–6.PubMedGoogle Scholar
  117. 117.
    Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:188–93.PubMedGoogle Scholar
  118. 118.
    Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23:2661–8.PubMedGoogle Scholar
  119. 119.
    Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61–5.PubMedGoogle Scholar
  120. 120.
    Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:680–7.PubMedGoogle Scholar
  121. 121.
    Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001;72:1924–9.PubMedGoogle Scholar
  122. 122.
    Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000;96:2426–31.PubMedGoogle Scholar
  123. 123.
    Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390–7.PubMedGoogle Scholar
  124. 124.
    Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of severe acute graft-versus-host disease. Blood 2006;108 Suppl 1:5304a.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations